安进
AMGN274.710USD
+1.625+0.60%
收盘 09/17, 16:00（美东）报价延迟15分钟
147.88B总市值
22.34市盈率 TTM
关于 安进 公司
安进公司是一家生物技术公司。该公司发现、开发、制造和提供各种人类治疗药物。该公司专注于医疗需求尚未得到满足的领域，并利用其专业知识努力寻求改善健康结果和改善人们生活的解决方案。该公司在人类治疗领域开展业务。该公司的上市产品组合包括Aranesp、ENBREL、Prolia（地诺单抗）、Neulasta（聚乙二醇非格司亭）、Otezla、XGEVA、Aranesp（达贝泊汀阿尔法）、KYPROLIS、Repatha（evolocumab）、Nplate（romiplostim）、Vectibix（帕尼单抗）、MVASI（贝伐珠单抗-awwb）、Parsabiv (etelcalcetide)、EPOGEN (epoetin alfa)、KANJINTI (曲妥珠单抗-anns)、BLINCYTO (blinatumomab)、Aimovig (erenumab-aooe)、EVENITY (romosozumab-aqqg)、AMGEVITATM (阿达木单抗)、Sensipar/Mimpara (西那卡塞)、NEUPOGEN (非格司亭)、IMLYGIC (他莫基因) laherparepvec）、Corlanor（伊伐布雷定）、 KYPROLIS（卡非佐米）、Maridebart 卡夫鲁肽（英夫利昔单抗-axxq）、Evenity、LumaKras、Nplate 和 XGeva 等。
公司简介
公司代码AMGN
公司名称Amgen Inc
上市日期Jun 17, 1983
CEOMr. Robert A. (Bob) Bradway
员工数量28000
证券类型Ordinary Share
年结日Jun 17
公司地址One Amgen Center Drive
城市THOUSAND OAKS
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编91320-1799
电话18054471000
网址https://www.amgen.com/
公司代码AMGN
上市日期Jun 17, 1983
CEOMr. Robert A. (Bob) Bradway
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
566.37K
+1.52%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
69.05K
+3.06%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
41.70K
+6.10%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
17.19K
+4.94%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.93K
+6.57%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
7.78K
-16.17%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
7.57K
+11.97%
Dr. Wanda M. Austin, Ph.D.
Dr. Wanda M. Austin, Ph.D.
Independent Director
Independent Director
7.35K
+12.36%
Ms. Nancy A. Grygiel
Ms. Nancy A. Grygiel
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
6.04K
-17.35%
Ms. Amy E. Miles
Ms. Amy E. Miles
Independent Director
Independent Director
4.84K
+20.06%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
566.37K
+1.52%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
69.05K
+3.06%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
41.70K
+6.10%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
17.19K
+4.94%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.93K
+6.57%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
7.78K
-16.17%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Other products
1.65B
20.21%
Prolia
1.10B
13.49%
Repatha
656.00M
8.05%
XGEVA
566.00M
6.95%
Enbrel
510.00M
6.26%
其他
3.67B
45.05%
地区USD
名称
营收
占比
US
5.34B
65.55%
ROW
2.09B
25.64%
业务
地区
业务USD
名称
营收
占比
Other products
1.65B
20.21%
Prolia
1.10B
13.49%
Repatha
656.00M
8.05%
XGEVA
566.00M
6.95%
Enbrel
510.00M
6.26%
其他
3.67B
45.05%
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.00%
State Street Global Advisors (US)
5.45%
BlackRock Institutional Trust Company, N.A.
5.36%
Capital International Investors
3.51%
Capital World Investors
3.13%
其他
72.54%
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.00%
State Street Global Advisors (US)
5.45%
BlackRock Institutional Trust Company, N.A.
5.36%
Capital International Investors
3.51%
Capital World Investors
3.13%
其他
72.54%
股东类型
持股股东
占比
Investment Advisor
53.27%
Investment Advisor/Hedge Fund
19.45%
Research Firm
4.96%
Pension Fund
2.21%
Bank and Trust
1.96%
Sovereign Wealth Fund
1.18%
Insurance Company
0.61%
Hedge Fund
0.50%
Individual Investor
0.17%
其他
15.69%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
4453
451.65M
83.89%
+6.94M
2025Q1
4519
453.49M
84.33%
+5.91M
2024Q4
4466
443.40M
82.54%
+89.78K
2024Q3
4316
438.01M
81.42%
-5.13M
2024Q2
4284
437.79M
81.61%
-4.94M
2024Q1
4192
436.25M
81.40%
-5.11M
2023Q4
4150
435.28M
81.36%
+42.25K
2023Q3
3990
429.94M
80.36%
-4.48M
2023Q2
3936
426.14M
79.65%
-4.34M
2023Q1
3951
427.29M
80.00%
-4.36M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
52.63M
9.79%
+145.69K
+0.28%
Mar 31, 2025
State Street Global Advisors (US)
29.18M
5.43%
-254.42K
-0.86%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
28.50M
5.3%
-289.51K
-1.01%
Mar 31, 2025
Capital International Investors
15.13M
2.81%
+2.92M
+23.93%
Mar 31, 2025
Capital World Investors
16.70M
3.11%
+10.21M
+157.12%
Mar 31, 2025
Geode Capital Management, L.L.C.
12.73M
2.37%
+252.31K
+2.02%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
12.21M
2.27%
-999.66K
-7.57%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
11.11M
2.07%
-33.38K
-0.30%
Jun 30, 2025
PRIMECAP Management Company
12.39M
2.3%
-613.83K
-4.72%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
8.73M
1.62%
+352.70K
+4.21%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
VanEck Biotech ETF
16.29%
FT Vest DJIA Dogs 10 Target Income ETF
10.17%
ProShares Ultra Nasdaq Biotechnology
7.79%
Amplify Weight Loss Drug & Treatment ETF
7.17%
Invesco Nasdaq Biotechnology ETF
6.93%
iShares Biotechnology ETF
6.85%
Invesco Biotechnology & Genome ETF
5.28%
Invesco Pharmaceuticals ETF
5.16%
Invesco Dow Jones Industrial Average Dividend ETF
5.11%
Invesco QQQ Low Volatility ETF
4.51%
查看更多
VanEck Biotech ETF
占比16.29%
FT Vest DJIA Dogs 10 Target Income ETF
占比10.17%
ProShares Ultra Nasdaq Biotechnology
占比7.79%
Amplify Weight Loss Drug & Treatment ETF
占比7.17%
Invesco Nasdaq Biotechnology ETF
占比6.93%
iShares Biotechnology ETF
占比6.85%
Invesco Biotechnology & Genome ETF
占比5.28%
Invesco Pharmaceuticals ETF
占比5.16%
Invesco Dow Jones Industrial Average Dividend ETF
占比5.11%
Invesco QQQ Low Volatility ETF
占比4.51%
分红派息
近5年累计派现
21.35B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Dec 10, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 07, 2025
Feb 14, 2025
Oct 25, 2024
AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024
Nov 18, 2024
Dec 09, 2024
Nov 18, 2024
Aug 02, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 06, 2024
Aug 16, 2024
Mar 06, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024
May 17, 2024
Jun 07, 2024
May 16, 2024
Dec 12, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024
Feb 16, 2024
Mar 07, 2024
Feb 15, 2024
Oct 24, 2023
AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023
Nov 17, 2023
Dec 08, 2023
Nov 16, 2023
Aug 01, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Sep 08, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 08, 2023
Aug 17, 2023
Mar 07, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Jun 08, 2023 going ex on May 17, 2023
May 18, 2023
Jun 08, 2023
May 17, 2023
Dec 12, 2022
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Mar 08, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 08, 2023
Feb 14, 2023
Oct 28, 2022
AMGN.NB Final Cash Dividend of gross USD 1.94 paid on Dec 08, 2022 going ex on Nov 16, 2022
Nov 17, 2022
Dec 08, 2022
Nov 16, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
